| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:SD-7300
CAS:748120-89-0
Package:50mg/RMB 16800
|
|
| | 4-Piperidinecarboxamide, N-hydroxy-1-(2-methoxyethyl)-4-[[4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl]sulfonyl]- Basic information |
| | 4-Piperidinecarboxamide, N-hydroxy-1-(2-methoxyethyl)-4-[[4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl]sulfonyl]- Chemical Properties |
| density | 1.43±0.1 g/cm3(Predicted) | | pka | 9.36±0.23(Predicted) |
| | 4-Piperidinecarboxamide, N-hydroxy-1-(2-methoxyethyl)-4-[[4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl]sulfonyl]- Usage And Synthesis |
| Uses | SD-7300 (SC-81490) is an orally active inhibitor of MMP-2, MMP-9, and MMP-13 with Ki values ??of 0.03, 0.01, and 0.03 nM, respectively. SD-7300 can reduce the degradation of extracellular matrix by tumor cells, thereby inhibiting the invasion and metastasis of tumor cells. In addition, SD-7300 is also a dose-dependent inhibitor of mouse corneal angiogenesis and an inhibitor of interleukin-1-induced bovine cartilage degradation. SD-7300 can be used in breast cancer research[1]. | | IC 50 | MMP-2: 0.03 nM (Ki); MMP-9: 0.01 nM (Ki); MMP13: 0.03 nM (Ki) | | References | [1] Winer, et al. "Inhibition of breast cancer metastasis by presurgical treatment with an oral matrix metalloproteinase inhibitor: a preclinical proof-of-principle study." Molecular cancer therapeutics 15.10 (2016): 2370-2377. DOI:10.1158/1535-7163.MCT-16-0194 |
| | 4-Piperidinecarboxamide, N-hydroxy-1-(2-methoxyethyl)-4-[[4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl]sulfonyl]- Preparation Products And Raw materials |
|